Traduction de «these data are not presented » (Néerlandais → Français) :

114 These data are not presented in detail in this report. 8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%
8.2.2.2 Inequalities in the indicators of accessibility The percentage of households reporting to have delayed contacts with the health system for financial reasons was strongly related to the income level, with 27% of delay in the households of the lowest quintile versus 4%

Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated. In addition to these 74 indicators, 11 indicators for which data are expected
Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated.

AIN457 Non-infectious uveitis 2011 III - Phase III study examining AIN457 for non-infectious uveitis in patients with Behcet’s disease did not meet its primary endpoint and the data do not support submission of AIN457 for this indication; based upon analysis of these data, Novartis will stop the extension study in Behcet’s uveitis
Indication potentielle/ Projet / domaine Soumissions Phase Mises à jour molécule thérapeutique prévues actuelle AIN457 Uveitis non infectieuse 2011 III - L’étude de phase III examinant AIN457 contre l’uveitis non infectieuse chez les patients atteints de la maladie de Behcet n’a pas satisfait au critère principal et les résultats sont insuffisants pour justifier le dépôt d’une demande d’autorisation pour cette indication, Novartis arrêtera l’extension de cette étude à l’uveitis de Behcet

After two weeks, these patients are contacted by telephone and asked the following questions: Has there been any contact with the GP during these two weeks? If not, why not?
Après 2 semaines, le patient est appelé et on lui pose les questions suivantes: Y a-t-il eu contact avec le médecin généraliste dans les 2 semaines et si ce n’est pas le cas, pour quelle raison; si oui, comment ce contact a-t-il été ressenti?

Though the quality of the somatic and medical care administered upon admittance does not differ from that provided for other emergencies, we do know that there are a series difficulties involved in the manner in which suicidal patients are to be managed and that these difficulties are not or badly taken into account by some emergency services:
Si la prise en charge somatique et les soins médicaux qui sont posés lors de cette admission ne diffèrent pas des autres situations d’urgence en qualité, nous savons que la prise en charge de la crise suicidaire pose une série de difficultés qui elles ne sont pas ou mal prises en compte par certains services d’urgence:

These core measures are not, and should not be viewed as, a substitute for IFRS measures.
Elles ne sont pas destinées à se substituer aux mesures IFRS et ne doivent pas être considérées comme telles.

Although the results did not meet statistical significance, these were the first data to suggest this survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting immediately following surgery.
Bien que n’étant pas significatifs du point de vue statistique, ces résultats ont été les premiers à suggérer que, dans une monothérapie suivant immédiatement l’intervention chirurgicale, l’inhibiteur de l’aromatase offrait un bénéfice de survie par rapport au tamoxifène.

scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling Randomisation: good concealment of allocation: no Blinding of outcome assessors: unclear Baseline characteristics comparable: yes Follow-up: sufficient Intention-to-treat: yes Contamination: unclear
scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling

These data build on the one-year Phase III TRANSFORMS study presented at the American Academy of Neurology meeting in April 2009 showing that FTY720 significantly reduced relapses more than interferon beta-1a (Avonex ® ), a standard of care in RRMS.
Les données récoltées par l’étude d’un an TRANSFORMS de phase III présentées au congrès de l’Académie Américaine de Neurologie en avril 2009 montrent que FTY720 réduit de manière clairement plus importante les rechutes que l’interféron beta-1a (Avonex ® ), qui est la norme de soins de la SEP cyclique.

These core measures are presented solely to permit investors to more fully understand how the Group’s management assesses underlying performance.
Ces mesures core sont présentées uniquement dans le but de permettre aux investisseurs de mieux comprendre comment la direction du Groupe évalue la performance sousjacente.